The cluster is too small to drive a directional trade. Monitor for any Form 4 filings by CEO/CFO in the next 30 days, if they also sell, that would be a more credible bearish signal. The offering extended cash runway into H1 2028, reducing near-term financing risk.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 20 $29.45entry
- T+1 · 6mo ago +3.70%α +3.51% · $30.54
- T+5 · 6mo ago +1.39%α −0.41% · $29.86
- T+20 · 5mo ago +11.38%α +10.63% · $32.80
- T+60 · 3mo ago +19.32%α +14.32% · $35.14
Price Chart
How similar events traded
Executive Summary
Two C-suite insiders at Pharvaris sold a combined $560K in open-market sales on May 15, 2026, just 11 days after the company completed a ~$107.5M public offering at $29.68 per share. The sales are small relative to the $2.0B market cap (0.03%) and likely reflect post-offering liquidity/vesting rather than a bearish signal, but the proximity to the dilutive raise warrants attention.
Key Financial Metrics
Key Facts
- Chief Commercial Officer Wim Souverijns sold 10,000 shares at $29.92 for $299K on May 15, 2026.
- Chief Technical Ops Officer Stefan Andreas Abele sold 8,748 shares at $29.82 for $261K on May 15, 2026.
- Total insider sales of $560K represent 0.03% of Pharvaris's $2.0B market cap.
- Sales occurred 11 days after a $107.5M public offering at $29.68 per share (424B5 filed May 8, 2026).
- Both insiders sold on the same day, suggesting a shared liquidity event (e.g., post-offering blackout window opening) rather than coordinated bearish conviction.
- Prior 30-day insider activity showed 4 sells totaling $1.4M, consistent with routine post-IPO/offering patterns.
Financial Impact
Total insider sales of $560K, trivial relative to $2.0B market cap and $107.5M offering proceeds.
Risk Factors
- Further insider selling by C-suite could signal lack of confidence in near-term catalysts.
- Post-offering dilution of ~3.9M shares may pressure stock in the short term.
- Clinical-stage biotech binary risk: any pipeline setback could amplify insider selling patterns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1779230721685 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers